Solid Biosciences Inc. Common Stock
SLDB US83422E2046
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -78% | -80% | 9% | -36% | 6% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Kahn Clare |
5.34 USD |
1,860 Bought |
9,924 USD |
11/03/2025 | 11/03/2025 |
| Ganot Ilan |
3.96 USD |
1,711 Sold |
6,776 USD |
13/02/2025 | 14/02/2025 |
| Herzich Paul CTO |
3.96 USD |
2,688 Sold |
10,644 USD |
13/02/2025 | 14/02/2025 |
| Howton David T COO |
3.96 USD |
5,561 Sold |
22,022 USD |
13/02/2025 | 14/02/2025 |
| Tan Kevin CFO |
3.96 USD |
3,164 Sold |
12,529 USD |
13/02/2025 | 14/02/2025 |
| Cumbo Alexander CEO |
3.96 USD |
11,365 Sold |
45,005 USD |
13/02/2025 | 14/02/2025 |
| Brooks Gabriel CMO |
3.96 USD |
3,256 Sold |
12,894 USD |
13/02/2025 | 14/02/2025 |
| Hanrahan Jessie SR OFF |
3.96 USD |
3,079 Sold |
12,193 USD |
13/02/2025 | 14/02/2025 |
| Ganot Ilan |
3.11 USD |
144 Sold |
448 USD |
27/01/2025 | 28/01/2025 |
| Tan Kevin CFO |
3.89 USD |
4,073 Sold |
15,849 USD |
09/01/2025 | 10/01/2025 |